Cipla jumps over 2 per cent on launching real-time COVID-19 detection kit in line with RT-PCR

Cipla announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for detection of COVID-19 in India. This product of the company comes in partnership with Ubio Biotechnology Systems Pvt Limited.  

ViraGen will be Cipla’s third offering in the COVID-19 testing segment. The company already has partnerships for antibody detection kit and antigen test kits thereby, strengthening the country’s fight against COVID-19.  

ViraGen is a real-time detection kit, which has been approved by Indian Council of Medical Research (ICMR). It is based on multiplex PCR technology, which helps to identify & detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity rate of 98.6 per cent along with the specificity of 98.8 per cent as compared to a standard ICMR test.   

This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected to be affected with the deadly disease. It will be manufactured by Ubio Biotechnology Systems as well as marketed & distributed by Cipla via its expansive distribution network across the country.  

Cipla is staying true to its promise of providing quality access to healthcare and is at the forefront of COVID care with the largest portfolio of offerings including protection, detection, treatment, and post-recovery.  

At 11.37 am on Thursday, the shares of the company were trading 2.48 per cent higher at Rs 926.45 per share on BSE.

---